Collegium Pharmaceutical Inc. (COLL)
$24.61
$-0.74
(-2.92%)
As on 31-Aug-2026 16:00EDT
Market cap
$786 Mln
Revenue (TTM)
$808 Mln
P/E Ratio
20
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
4.7
-
Debt to Equity
3.3
-
Book Value
$--
-
EPS
$1.1
-
Face value
--
-
Shares outstanding
30,999,193
10 Years Aggregate
CFO
$612.07 Mln
EBITDA
$191.58 Mln
Net Profit
$-140.07 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| -46.8 | -31.6 | -26.8 | -36.6 | 1.4 | 3.9 | 10.6 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
| 61.6 | -6.9 | 32.7 | 24.2 | -6.7 | -2.7 | 19.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical (COLL)
|
24.6 | 785.8 | 808.2 | 47.9 | 29.6 | 15.6 | 20 | 2.8 |
| 17.5 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 198.5 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.1 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.0 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.1 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.2 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 139.0 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Collegium Pharmaceutical (COLL)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription... medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. Read more
-
Co-Founder & Independent Chairman
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
-
Co-Founder & Independent Chairman
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.
-
Headquarters
Stoughton, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Collegium Pharmaceutical (COLL)
What is the current share price of Collegium Pharmaceutical Inc (COLL) Today?
The share price of Collegium Pharmaceutical Inc (COLL) is $24.61 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Collegium Pharmaceutical Inc (COLL) has given a return of 1.44% in the last 3 years.
What is the current PB & PE ratio of Collegium Pharmaceutical Inc (COLL)?
The P/E ratio of Collegium Pharmaceutical Inc (COLL) is 19.96 times as on 28-Aug-2026, a 47 discount to its peers’ median range of 37.32 times.
The P/B ratio of Collegium Pharmaceutical Inc (COLL) is 2.75 times as on 28-Aug-2026, a 65 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
29.24 |
6.09 |
2024 |
16.61 |
5.02 |
2023 |
26.71 |
6.58 |
2022 |
-31.16 |
4.00 |
2021 |
8.91 |
3.14 |
What is the 52 Week High and Low of Collegium Pharmaceutical Inc (COLL)?
The 52-week high and low of Collegium Pharmaceutical Inc (COLL) are Rs 50.79 and Rs 24.47 as of 01-Sep-2026.
What is the market cap of Collegium Pharmaceutical Inc (COLL)?
Collegium Pharmaceutical Inc (COLL) has a market capitalisation of $ 786 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Collegium Pharmaceutical Inc (COLL)?
Before investing in Collegium Pharmaceutical Inc (COLL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.